- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00516659
ETEC Logistics Trial (TREK) (Trek)
A Phase II, Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Epidemiology of Natural Infection With Enterotoxigenic Escherichia Coli Occurring After Transcutaneous Immunization in a Field Setting
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The primary objectives of the study are to evaluate the incidence of ETEC illness in a field setting and to compare the safety of LT delivered by TCI with placebo. The secondary objectives include, but are not limited to:
evaluate the stool frequency per episode of ETEC illness in placebo recipients, to evaluate the immunogenicity of LT delivered by TCI, to evaluate the incidence of IBS following travel to areas of ETEC endemnicity, and to evaluate the incidence of VPO in placebo and LT patch recipients.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
Antigua Guatemala, Guatemala, 03001
- Private Clinic Antigua
-
-
-
-
Guanajuata
-
San Miguel de Allende, Guanajuata, Mexico, 37700
- Private Clinic San Miguel
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44690
- Private Clinic Guadalajara
-
-
Marina Vallarta
-
Puerto Vallarta, Marina Vallarta, Mexico, 48334
- AmeriMed Hospital
-
-
Morelos
-
Cuernavaca, Morelos, Mexico, 62250
- Private Clinic Cuernavaca
-
-
Quintana Roo
-
Cancun, Quintana Roo, Mexico, 77500
- Hospital Americano
-
-
-
-
California
-
Long Beach, California, Verenigde Staten, 90806
- West Coast Clinical Trials
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60610
- Radiant Research
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21205
- Johns Hopkins University, Bloomberg School of Public Health
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55430
- Twin Cities Clinical Research
-
-
New Jersey
-
Hackensack, New Jersey, Verenigde Staten, 07601
- Advanced Biomedical Research
-
-
New York
-
Ithica, New York, Verenigde Staten, 14850
- Asthma Allergy & Associates
-
-
Ohio
-
Columbus, Ohio, Verenigde Staten, 43212
- Radiant Research
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75235
- Radiant Research
-
Houston, Texas, Verenigde Staten, 77024
- Breco Research
-
Houston, Texas, Verenigde Staten, 77030
- Center for Infectious Diseases, The University of Texas Health Science Center at Houston
-
San Antonio, Texas, Verenigde Staten, 78229
- Radiant Research
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84124
- Jean Brown Research
-
-
Washington
-
Tacoma, Washington, Verenigde Staten, 98418
- Northwest Kinetics
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Healthy adult men and women 18-64 years of age inclusive at screening
- Signed Informed Consent form
- Planned travel to an area within 2 ½ hours traveling distance of Cuernavaca or Guadalajara, Mexico or Antigua, Guatemala (minimum stay of 7 days)
- If female who is not post-menopausal or surgically sterile, negative pregnancy test (within 24 hours prior to vaccination) and agreement to employ an effective form of birth control or practice abstinence through the end of the study.
Exclusion Criteria:
- Clinically significant abnormalities as determined by the Investigator/clinician during physical inspection
- Received investigational product from 30 days before date of first vaccination or during the entire study period
- Ever received LT, ETEC, or cholera vaccine
- History of traveler's diarrhea within the previous year
- Travel to a developing country within the last year
- Women who are pregnant or breastfeeding
- History of achlorhydria
- Evidence of immunosuppression, including concomitant immunosuppressive therapy; fever > 99.5°F (37.5°C) on day of vaccination
- Current problems with alcohol or substance abuse
- An employee of the study clinic
- Sensitivity or allergy to any of the vaccine components
- History of significant blood loss, blood product donation, or blood product recipient in the previous 60 days
- Planned use of Imodium or antibiotics for self treatment of diarrhea during the study period
- Visible tattoos or marks (tattoos/scars) at the vaccination areas that would prevent appropriate dermatologic monitoring of the vaccination sites; and
- Medical history of acute or chronic GI illness or major GI surgery.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Toewijzing: Gerandomiseerd
- Interventioneel model: Faculteitstoewijzing
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: Group 1
Group 1 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 37.5µg LT
|
Subjects in Group 1 will receive two vaccinations of a patch containing 37.5µg LT 2 to 3 weeks apart.
|
Placebo-vergelijker: Group 2
Group 2 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 0µg LT (placebo patch containing no LT)
|
The placebo patch contains all of the components of the active patch, but with no LT included in the formulation.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Incidence of Enterotoxigenic Escherichia coli (ETEC) illness defined as a diarrheal episode associated with an LT, LT/ST, or ST-positive ETEC strain isolated from a sample of a stool
Tijdsspanne: during the diarrheal episode or within 48 hours after the last stool in the diarrheal episode.
|
during the diarrheal episode or within 48 hours after the last stool in the diarrheal episode.
|
Safety of heat-labile enterotoxin of Escherichia coli (LT) delivered by transcutaneous immunization (TCI) vs placebo
Tijdsspanne: From vaccination 1 to completion of Day 180 follow-up, about a seven month time period
|
From vaccination 1 to completion of Day 180 follow-up, about a seven month time period
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Stool frequency per episode of ETEC illness in placebo recipients
Tijdsspanne: Duration of stay in Mexico or Guatemala assessed up to four weeks
|
Duration of stay in Mexico or Guatemala assessed up to four weeks
|
Immunogenicity of LT delivered by TCI
Tijdsspanne: at least three weeks prior to arrival in country, arrival in Mexico or Guatemala, and 5 to 18 days after arrival
|
at least three weeks prior to arrival in country, arrival in Mexico or Guatemala, and 5 to 18 days after arrival
|
Incidence of irritable bowel syndrome following travel to areas of ETEC endemnicity.
Tijdsspanne: Baseline through six months post return from Latin America. A period of about six months.
|
Baseline through six months post return from Latin America. A period of about six months.
|
Incidence of vaccine preventable outcome in placebo and LT patch recipients.
Tijdsspanne: Duration of each individual participant stay in Mexico or Guatemala ranging from 7 to 28 Days.
|
Duration of each individual participant stay in Mexico or Guatemala ranging from 7 to 28 Days.
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Herbert L. DuPont, MD, Center for Infectious Diseases, The University of Texas Health Science Center at Houston
- Hoofdonderzoeker: Robin McKenzie, MD, Johns Hopkins University, Bloomberg School of Public Health
- Hoofdonderzoeker: Rama Yerramsetti, Breco Research, Houston, TX
- Hoofdonderzoeker: William P Jennings, Radiant Research, San Antonio, TX
- Hoofdonderzoeker: Yu-Luen Hsu, West Coast Clinical Trials, Long Beach, CA
- Hoofdonderzoeker: Christopher A Smith, Asthma & Allergy Associates, Ithaca, NY
- Hoofdonderzoeker: Benno G Roesch, Advanced Biomedical Research, Hackensack, NJ
- Hoofdonderzoeker: Jeffrey G Geohas, Radiant Research, Chicago, IL
- Hoofdonderzoeker: Gilbert Podolsky, Jean Brown Research, Salt Lake City, UT
- Hoofdonderzoeker: Thomas Lagen, Northwest Kinetics, Tacoma, WA
- Hoofdonderzoeker: Roy M Fleischmann, Radiant Research, Dallas, TX
- Hoofdonderzoeker: Douglas R Schumacher, Radiant Research, Columbus, OH
- Hoofdonderzoeker: Norman M Lunde, Twin Cities Clinical Research, Minneapolis, MN
- Hoofdonderzoeker: Francisco G Sandoval, Universidad Autonoma De Guadalajara, Mexico
- Hoofdonderzoeker: Juan Hector M Romero, Universidad Autonoma Guadalajara, Mexico
- Hoofdonderzoeker: Jaime B Gerson, University of Texas, Cuernavaca, Mexico
- Hoofdonderzoeker: Edwin Asturias, Universidad del Valle de Guatemala (Antigua)
- Hoofdonderzoeker: Roberto Garcia, AmeriMed Puerto Vallarta, Mexico
- Hoofdonderzoeker: Martha V Serrato, Hospital Americano, Cancun, Mexico
- Hoofdonderzoeker: Robert Maxwell, Private Clinic, San Miguel de Allende, Mexico
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- ELT206
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Heat-Labile Enterotoxin of Escherichia coli (LT)
-
National Institute of Allergy and Infectious Diseases...VoltooidGastro-enteritis Escherichia ColiVerenigde Staten
-
National Institute of Allergy and Infectious Diseases...Voltooid
-
National Institute of Allergy and Infectious Diseases...BeëindigdGastro-enteritis Escherichia Coli | ImmunisatieBangladesh